Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 2 | 2016 | 268 | 0.680 |
Why?
|
| Brain Neoplasms | 3 | 2016 | 1329 | 0.550 |
Why?
|
| Electromagnetic Fields | 1 | 2016 | 37 | 0.490 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 343 | 0.480 |
Why?
|
| Electric Stimulation Therapy | 1 | 2016 | 62 | 0.470 |
Why?
|
| Neoplasm Metastasis | 2 | 2026 | 688 | 0.450 |
Why?
|
| Patients | 1 | 2016 | 183 | 0.430 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 115 | 0.430 |
Why?
|
| Sleep Wake Disorders | 1 | 2016 | 314 | 0.360 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 259 | 0.360 |
Why?
|
| Breast Neoplasms | 4 | 2022 | 2382 | 0.340 |
Why?
|
| Refugees | 2 | 2023 | 83 | 0.340 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 641 | 0.280 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 925 | 0.240 |
Why?
|
| Ultrasonography, Mammary | 2 | 2016 | 17 | 0.240 |
Why?
|
| Uterine Neoplasms | 1 | 2026 | 98 | 0.220 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2023 | 21 | 0.190 |
Why?
|
| Radiation Oncology | 1 | 2023 | 82 | 0.180 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 142 | 0.180 |
Why?
|
| Radiosurgery | 1 | 2026 | 399 | 0.180 |
Why?
|
| Aged, 80 and over | 6 | 2026 | 8333 | 0.160 |
Why?
|
| Aged | 9 | 2026 | 26153 | 0.150 |
Why?
|
| Middle Aged | 11 | 2026 | 36215 | 0.150 |
Why?
|
| Retrospective Studies | 8 | 2026 | 17291 | 0.150 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2015 | 161 | 0.130 |
Why?
|
| Radiopharmaceuticals | 2 | 2015 | 205 | 0.130 |
Why?
|
| Granulomatous Mastitis | 1 | 2016 | 1 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 2769 | 0.120 |
Why?
|
| Asbestos | 1 | 2016 | 36 | 0.120 |
Why?
|
| Pleural Neoplasms | 1 | 2016 | 30 | 0.120 |
Why?
|
| Prognosis | 2 | 2016 | 4316 | 0.120 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 978 | 0.120 |
Why?
|
| Breast | 1 | 2016 | 156 | 0.120 |
Why?
|
| Mesothelioma | 1 | 2016 | 51 | 0.110 |
Why?
|
| Adult | 8 | 2020 | 40777 | 0.110 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 1471 | 0.110 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2015 | 5 | 0.110 |
Why?
|
| Female | 13 | 2026 | 78844 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 129 | 0.110 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2015 | 58 | 0.110 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 2664 | 0.110 |
Why?
|
| Rectal Neoplasms | 1 | 2015 | 159 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 969 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 1997 | 0.100 |
Why?
|
| Syria | 2 | 2023 | 5 | 0.100 |
Why?
|
| Turkey | 2 | 2023 | 21 | 0.090 |
Why?
|
| Hysterectomy | 1 | 2014 | 138 | 0.090 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 310 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 331 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 506 | 0.090 |
Why?
|
| Bone and Bones | 1 | 2015 | 317 | 0.090 |
Why?
|
| Environmental Exposure | 1 | 2016 | 578 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 1189 | 0.080 |
Why?
|
| Humans | 14 | 2026 | 145474 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1963 | 0.080 |
Why?
|
| Chemoradiotherapy | 2 | 2023 | 239 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1321 | 0.070 |
Why?
|
| Survival Rate | 1 | 2014 | 2090 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2016 | 1146 | 0.070 |
Why?
|
| Male | 8 | 2023 | 72842 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 5423 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2026 | 1149 | 0.070 |
Why?
|
| Quality of Life | 1 | 2016 | 3204 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 91 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 1508 | 0.040 |
Why?
|
| Etoposide | 1 | 2020 | 168 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2016 | 8057 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 257 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2026 | 11772 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2022 | 587 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1374 | 0.030 |
Why?
|
| Thioredoxins | 1 | 2016 | 30 | 0.030 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2016 | 61 | 0.030 |
Why?
|
| Syndecan-1 | 1 | 2016 | 43 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2016 | 81 | 0.030 |
Why?
|
| Whole Body Imaging | 1 | 2015 | 29 | 0.030 |
Why?
|
| Epidermal Cyst | 1 | 2015 | 13 | 0.030 |
Why?
|
| Touch | 1 | 2015 | 39 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 331 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 122 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 156 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2015 | 112 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2015 | 165 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2015 | 157 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2016 | 635 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2121 | 0.020 |
Why?
|
| Peptides | 1 | 2016 | 998 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 3623 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 3413 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3904 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2015 | 2970 | 0.010 |
Why?
|